Suppr超能文献

2004年至2011年间意大利前列腺癌放疗发生了怎样的变化?意大利放射治疗与临床肿瘤学会(AIRO)泌尿肿瘤研究组对全国实践模式(POP)数据库的分析。

How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO).

作者信息

Mazzeo Ercole, Triggiani Luca, Frassinelli Luca, Guarneri Alessia, Bartoncini Sara, Antognoni Paolo, Gottardo Stefania, Greco Diana, Borghesi Simona, Nanni Sara, Bruni Alessio, Ingrosso Gianluca, D'Angelillo Rolando Maria, Detti Beatrice, Francolini Giulio, Magli Alessandro, Guerini Andrea Emanuele, Arcangeli Stefano, Spiazzi Luigi, Ricardi Umberto, Lohr Frank, Magrini Stefano Maria

机构信息

Radiotherapy Unit, Oncology and Hematology Department, University Hospital of Modena, 41124 Modena, Italy.

Radiation Oncology Department, University and Spedali Civili Hospital, 25123 Brescia, Italy.

出版信息

Cancers (Basel). 2021 May 30;13(11):2702. doi: 10.3390/cancers13112702.

Abstract

BACKGROUND AND PURPOSE

Two previous "Patterns Of Practice" surveys (POP I and POP II), including more than 4000 patients affected by prostate cancer treated with radical external beam radiotherapy (EBRT) between 1980 and 2003, established a "benchmark" Italian data source for prostate cancer radiotherapy. This report (POP III) updates the previous studies.

METHODS

Data on clinical management and outcome of 2525 prostate cancer patients treated by EBRT from 2004 to 2011 were collected and compared with POP II and, when feasible, also with POP I. This report provides data on clinical presentation, diagnostic workup, radiation therapy management, and toxicity as collected within the framework of POP III.

RESULTS

More than 50% of POP III patients were classified as low or intermediate risk using D'Amico risk categories as in POP II; 46% were classified as ISUP grade group 1. CT scan, bone scan, and endorectal ultrasound were less frequently prescribed. Dose-escalated radiotherapy (RT), intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), and hypofractionated RT were more frequently offered during the study period. Treatment was commonly well tolerated. Acute toxicity improved compared to the previous series; late toxicity was influenced by prescribed dose and treatment technique. Five-year overall survival, biochemical relapse free survival (BRFS), and disease specific survival were similar to those of the previous series (POP II). BRFS was better in intermediate- and high-risk patients treated with ≥ 76 Gy.

CONCLUSIONS

This report highlights the improvements in radiotherapy planning and dose delivery among Italian Centers in the 2004-2011 period. Dose-escalated treatments resulted in better biochemical control with a reduction in acute toxicity and higher but acceptable late toxicity, as not yet comprehensively associated with IMRT/IGRT. CTV-PTV margins >8 mm were associated with increased toxicity, again suggesting that IGRT-allowing for tighter margins-would reduce toxicity for dose escalated RT. These conclusions confirm the data obtained from randomized controlled studies.

摘要

背景与目的

此前的两项“实践模式”调查(POP I和POP II)纳入了1980年至2003年间接受根治性外照射放疗(EBRT)的4000多名前列腺癌患者,建立了前列腺癌放疗的意大利“基准”数据源。本报告(POP III)对先前的研究进行了更新。

方法

收集了2004年至2011年间接受EBRT治疗的2525例前列腺癌患者的临床管理和结局数据,并与POP II进行比较,在可行的情况下,还与POP I进行比较。本报告提供了在POP III框架内收集的关于临床表现、诊断检查、放射治疗管理和毒性的数据。

结果

与POP II一样,超过50%的POP III患者根据达米科风险分类被归类为低风险或中风险;46%被归类为国际泌尿病理学会(ISUP)1级组。CT扫描、骨扫描和直肠内超声的开具频率较低。在研究期间,剂量递增放疗(RT)、调强放疗(IMRT)图像引导放疗(IGRT)和大分割放疗的提供频率更高。治疗通常耐受性良好。与前一组相比,急性毒性有所改善;晚期毒性受规定剂量和治疗技术的影响。五年总生存率、无生化复发生存率(BRFS)和疾病特异性生存率与前一组(POP II)相似。接受≥76 Gy治疗的中高危患者的BRFS更好。

结论

本报告强调了2004 - 2011年期间意大利各中心在放疗计划和剂量给予方面的改进。剂量递增治疗导致更好的生化控制,急性毒性降低,晚期毒性虽较高但可接受,因为尚未与IMRT/IGRT全面关联。临床靶区(CTV)至计划靶区(PTV)的边缘>8 mm与毒性增加相关,这再次表明允许更窄边缘的IGRT将降低剂量递增放疗的毒性。这些结论证实了从随机对照研究中获得的数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03f/8199007/28efcb717260/cancers-13-02702-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验